Mentari Upsizes Pre-Merger Private Placement by $200M at 52.8% Premium, Extending Cash Runway into 2029
INM has more than doubled off its 52-week low of $0.575 on elevated volume (21× avg).
Summary
Mentari Therapeutics upsized its pre-merger private placement by $200 million at a 52.8% premium, bringing total pre-closing financing to $490 million and extending the combined company's cash runway into 2029.
Key Events · M&A and Partnerships · INM
-
$200M Upsized Private Placement at Premium
Mentari Therapeutics entered into an amendment to its Securities Purchase Agreement, adding $200 million in additional shares and pre-funded warrants at a per-share price equal to 152.8% of the original private placement price, bringing total pre-closing financing to $490 million.
-
Cash Runway Extended into 2029
The additional proceeds are expected to fund operations into 2029, covering Phase 2a readouts for both PACAP-targeted lead programs (including MT-002) and supporting the broader migraine prevention pipeline.
-
Top-Tier Healthcare Investors Join
New investors include Fairmount, ADAR1 Capital Management, Venrock Healthcare Capital Partners, Sirenia Capital Management LP, Janus Henderson Investors, Blackstone Multi-Asset Investing, RTW Investments, Deep Track Capital, Vivo Capital, Commodore Capital, and BB Biotech.
-
Pro Forma Ownership and Share Count
Post-merger, pre-Merger Mentari stockholders will own approximately 98.85% of the combined company, with InMed shareholders owning approximately 1.15%. Total shares outstanding on an as-converted/as-exercised basis are expected to be approximately 601,195,812.
Analysis · INM · Life Sciences
Mentari Therapeutics, the private company merging with InMed, has upsized its pre-closing financing by $200 million at a 52.8% premium to the original per-share price, bringing total pre-merger funding to $490 million. The premium pricing signals strong institutional demand from top-tier healthcare investors. The additional capital extends the combined company's cash runway into 2029, funding both PACAP-targeted lead programs through Phase 2a readouts and supporting the broader migraine prevention pipeline. This materially de-risks the merger and the combined entity's near-term financing needs, though InMed shareholders will be diluted to approximately 1.15% ownership post-merger.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 42% of the 419 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INM was trading at $1.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.5M. The 52-week trading range was $0.58 to $2.75. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.